Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1903 in Relapsed/Refractory Hematologic Malignancies
NCT05055791Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of syhx1903 in hematologic malignancy, acute myeloid leukemia (AML), lymphoma and 1 more (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose limiting toxicities at 28 days, Incidence of adverse events at 1 year and 1 more. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
syhx1903
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05055791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055791.